摘要:
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要:
Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
摘要:
Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
摘要:
Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.
摘要:
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要:
Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.
摘要:
The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
摘要翻译:本发明涉及含有氨基酸序列的肿瘤相关肽,其选自所附列举的SEQ ID NO:1至SEQ ID NO:79。 该肽具有结合人类主要组织相容性复合体(MHC)I类分子的能力。 本发明还涉及肽用于制备药物和治疗肿瘤疾病的用途。 本发明还涉及包含至少一种肽的药物组合物。
摘要:
The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
摘要:
The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID-No. 1 to SEQ ID-No. 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.
摘要翻译:本发明涉及具有选自SEQ ID NO:1的氨基酸序列的肿瘤相关肽。 1至SEQ ID No。 101,其中肽具有结合人类主要组织相容性复合物(MHC)I类分子的能力。 此外,本发明涉及肽和编码肽的核酸用于制备药物以及用于治疗肿瘤疾病和/或腺瘤性疾病的用途。 此外,描述了具有至少一种肽的药物组合物。
摘要:
The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
摘要翻译:本发明涉及含有氨基酸序列的肿瘤相关肽,其选自所附列举的SEQ ID NO:1至SEQ ID NO:79。 该肽具有结合人类主要组织相容性复合体(MHC)I类分子的能力。 本发明还涉及肽用于制备药物和治疗肿瘤疾病的用途。 本发明还涉及包含至少一种肽的药物组合物。